Skip to main content
. 2021 Sep 6;13(17):4483. doi: 10.3390/cancers13174483

Figure 9.

Figure 9

PLK1 inhibitor reduces OIP5-mediated pRCC tumorigenesis. (A,B) RNA-seq and real-time PCR analyses of PLK1 expression in ACHN EV and ACHN OIP5 tumors. RNA-seq was performed in 3 each from ACHN EV and ACHN OIP5 tumors. (C) ACHN EV and ACHN OIP5 cells were treated with DMSO (−) or the PLK1 inhibitor (BI2536) in 40 nM PLK1 inhibitor for 72 h, followed by quantification of cell cycle distributions. Experiments were repeated 3 times; means ± SEMs are graphed. **: p < 0.01, ***: p < 0.001, ****: p < 0.0001 in the indicated comparisons by 2-tailed Student’s test. (D–G) Mice bearing ACHN EV or ACHN OIP5 tumors were treated with vehicle or BI2536 (50 mg/kg) intravenously. The overall profiles of tumor growth in the vehicle treated setting (D); tumor volumes were recorded following treatments (E–G). Statistical analyses were performed using 2-tailed Student’s t-test; *: p < 0.05, ***: p < 0.001. (H) Kaplan Meier curve for the indicated mice reaching endpoints. Statistical analysis was performed using logrank test.